Skip to main content

Table 6 Relationship between BRCA1/2 methylation and clinicopathological variables in sporadic breast carcinomas

From: BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers

Sporadic carcinomas Grades 1–2 vs. 3 Ductal vs. lobular tumors ER-positive vs. ER-negative PR-positive vs. PR-negative HER2-positive vs. HER2-negative
Probe Test statistica p Value Test statistica p Value Test statistica p Value Test statistica p Value Test statistica p Value
BRCA1.1 12.230b 0.001* 1.852b 0.342 7.577b 0.011* 6.753b 0.016* 0.176b 0.533
BRCA1.2 8.190c 0.006* 0.026b 1.000 6.689c 0.014* 3.762c 0.071 2.825b 0.125
BRCA1.3 12.230b 0.001* 1.852b 0.342 7.577b 0.011* 6.753b 0.016* 0.176b 0.533
BRCA1 totalc 8.190c 0.006* 0.026b 1.000 6.689c 0.014* 3.762c 0.071 2.825b 0.125
BRCA2.1 6.577b 0.015* 1.659b 0.345 0.706b 0.462 0.274b 0.736 3.688b 0.115
BRCA2.2 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
BRCA2.3 2.775b 0.178 0.297b 1.000 5.084b 0.080 0.137b 1.000 0.137b 1.000
BRCA2.4 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
BRCA2 totalc 6.577b 0.015* 1.659c 0.345 0.706c 0.462 0.274c 0.736 3.688c 0.115
  1. Abbreviations: ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, N/A Not applicable, because one of the two variables (either the methylation probe or the clinicopathological variable) was a constant, PR Progesterone receptor
  2. aPearson’s chi-square test or Fisher’s exact test
  3. bFisher’s exact test
  4. cPearson’s chi-square test
  5. *Statistically significant (two-sided p value <0.05)